Xiaomin Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaomin Luo has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
- Mingyue Zheng
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
30 shared publications Dingyan Wang
Lingang Laboratory, Shanghai 200031, China
11 shared publicationsKaixian Chen
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China
11 shared publicationsJie Yu
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
9 shared publications- Xutong Li
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
9 shared publications Hualiang Jiang
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
8 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Evaluating generative models for structure-based drug discovery from de novo design to lead optimization
- 1 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEvaluating generative models for structure-based drug discovery from de novo design to lead optimization
- 30 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18838-18855
Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers
Targeting methionine adenosyltransferase 2A (MAT2A) represents an attractive synthetic lethal approach for treating methylthioadenosine phosphorylase (MTAP)-deleted cancers. Despite promising progress in the development of MAT2A inhibitors, many reported compounds remain limited by insufficient selectivity, systemic toxicity, and the stereochemical complexities of atropisomerism. Through structure-guided optimization of our previously reported atropisomeric lead, we identified ZS97 (26), a potent MAT2A inhibitor that lacks axial chirality. The nonatropisomeric nature simplifies pharmacological development by avoiding the need for asymmetric synthesis or chiral resolution. ZS97 demonstrated potent enzymatic inhibition, effectively depleting intracellular SAM and suppressing downstream PRMT5-mediated methylation. This biochemical blockade selectively triggered the DNA damage response and cell growth inhibition in MTAP-deficient cancer cells. Furthermore, ZS97 exhibited favorable oral bioavailability and induced significant tumor inhibition in an NCI-H838 xenograft model without associated weight loss. These findings highlight ZS97 as a structurally optimized orally active candidate with therapeutic potential for MTAP-deficient cancers.
- 30 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18838-18855
Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers
Targeting methionine adenosyltransferase 2A (MAT2A) represents an attractive synthetic lethal approach for treating methylthioadenosine phosphorylase (MTAP)-deleted cancers. Despite promising progress in the development of MAT2A inhibitors, many reported compounds remain limited by insufficient selectivity, systemic toxicity, and the stereochemical complexities of atropisomerism. Through structure-guided optimization of our previously reported atropisomeric lead, we identified ZS97 (26), a potent MAT2A inhibitor that lacks axial chirality. The nonatropisomeric nature simplifies pharmacological development by avoiding the need for asymmetric synthesis or chiral resolution. ZS97 demonstrated potent enzymatic inhibition, effectively depleting intracellular SAM and suppressing downstream PRMT5-mediated methylation. This biochemical blockade selectively triggered the DNA damage response and cell growth inhibition in MTAP-deficient cancer cells. Furthermore, ZS97 exhibited favorable oral bioavailability and induced significant tumor inhibition in an NCI-H838 xenograft model without associated weight loss. These findings highlight ZS97 as a structurally optimized orally active candidate with therapeutic potential for MTAP-deficient cancers.
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Deep residual learning for molecular force fields
Accurate descriptions of interactions between atoms are essential for molecular simulations used to study biology and support drug discovery. Existing force fields often face a trade-off between physical reliability, computational efficiency, and accuracy across unfamiliar molecules. Here we show that Residual Learning Force Field, a hybrid machine learning force field, can reduce this trade-off by combining simple physics-based descriptions of bonded interactions with learned corrections for remaining energetic effects. The two components are trained together through a three-step strategy so that each contributes complementary information. In tests covering drug-like molecules, molecular dimers, torsional energy profiles, energy-minimum structures, and biomolecular simulations, Residual Learning Force Field gives accurate and stable predictions across diverse systems. These results suggest that combining physical constraints with data-driven corrections can provide a practical route toward more reliable and efficient molecular simulation for biological research and drug discovery.
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDeep residual learning for molecular force fields
Accurate descriptions of interactions between atoms are essential for molecular simulations used to study biology and support drug discovery. Existing force fields often face a trade-off between physical reliability, computational efficiency, and accuracy across unfamiliar molecules. Here we show that Residual Learning Force Field, a hybrid machine learning force field, can reduce this trade-off by combining simple physics-based descriptions of bonded interactions with learned corrections for remaining energetic effects. The two components are trained together through a three-step strategy so that each contributes complementary information. In tests covering drug-like molecules, molecular dimers, torsional energy profiles, energy-minimum structures, and biomolecular simulations, Residual Learning Force Field gives accurate and stable predictions across diverse systems. These results suggest that combining physical constraints with data-driven corrections can provide a practical route toward more reliable and efficient molecular simulation for biological research and drug discovery.
- 1 January 2026
- Published by Springer Nature
- p. 907-916
Drug Dosage Form Design
- 1 January 2026
- Published by Springer Nature
- p. 891-905
Prediction of Drug Crystal Structure
- Open Access
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Deep Residual Learning for Molecular Force Fields
Accurate interatomic interaction modeling via force fields is critical for biological studies and drug discovery, but balancing accuracy and generalizability remains challenging. We introduce ResFF (Residual Learning Force Field), a hybrid machine learning force field that employs deep residual learning to integrate physics-based learnable molecular mechanics covalent terms with residual corrections from a lightweight equivariant neural network. Through a three-stage joint optimization, the two components are trained in a complementary manner to achieve optimal performance. Benchmarks show ResFF outperforms classical and neural network force fields in generalization (mean absolute error (MAE): 1.16 kcal/mol on Gen2-Opt, 0.90 kcal/mol on DES370K), torsional profiles (MAE: 0.45/0.48 kcal/mol on TorsionNet-500 and Torison Scan), and intermolecular interactions (MAE: 0.32 kcal/mol on S66×8). It also enables precise energy minima reproduction and stable molecular dynamics of biological systems. ResFF merges physical constraints with neural expressiveness, offering a robust tool for accurate and efficient molecular simulation.
- 22 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDeep Residual Learning for Molecular Force Fields
Accurate interatomic interaction modeling via force fields is critical for biological studies and drug discovery, but balancing accuracy and generalizability remains challenging. We introduce ResFF (Residual Learning Force Field), a hybrid machine learning force field that employs deep residual learning to integrate physics-based learnable molecular mechanics covalent terms with residual corrections from a lightweight equivariant neural network. Through a three-stage joint optimization, the two components are trained in a complementary manner to achieve optimal performance. Benchmarks show ResFF outperforms classical and neural network force fields in generalization (mean absolute error (MAE): 1.16 kcal/mol on Gen2-Opt, 0.90 kcal/mol on DES370K), torsional profiles (MAE: 0.45/0.48 kcal/mol on TorsionNet-500 and Torison Scan), and intermolecular interactions (MAE: 0.32 kcal/mol on S66×8). It also enables precise energy minima reproduction and stable molecular dynamics of biological systems. ResFF merges physical constraints with neural expressiveness, offering a robust tool for accurate and efficient molecular simulation.
- 7 January 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (2) , 297-308
Prediction of Solvate Based on Graph Attention Network
- 7 January 2025
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 25 (2) , 297-308
Prediction of Solvate Based on Graph Attention Network
- Open Access
- 22 November 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (1)
miCGR: interpretable deep neural network for predicting both site-level and gene-level functional targets of microRNA
MicroRNAs (miRNAs) are critical regulators in various biological processes to cleave or repress translation of messenger RNAs (mRNAs). Accurately predicting miRNA targets is essential for developing miRNA-based therapies for diseases such as cancer and cardiovascular disease. Traditional miRNA target prediction methods often struggle due to incomplete knowledge of miRNA-target interactions and lack interpretability. To address these limitations, we propose miCGR, an end-to-end deep learning framework for predicting functional miRNA targets. MiCGR employs 2D convolutional neural networks alongside an enhanced Chaos Game Representation (CGR) of both miRNA sequences and their candidate target site (CTS) on mRNA. This advanced CGR transforms genetic sequences into informative 2D graphical representations based on sequence composition and subsequence frequencies, and explicitly incorporates important prior knowledge of seed regions and subsequence positions. Unlike one-dimensional methods based solely on sequence characters, this approach identifies functional motifs within sequences, even if they are distant in the original sequences. Our model outperforms existing methods in predicting functional targets at both the site and gene levels. To enhance interpretability, we incorporate Shapley value analysis for each subsequence within both miRNA sequences and their target sites, allowing miCGR to achieve improved accuracy, particularly with more lenient CTS selection criteria. Finally, two case studies demonstrate the practical applicability of miCGR, highlighting its potential to provide insights for optimizing artificial miRNA analogs that surpass endogenous counterparts.
- 22 November 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (1)
Open AccessmiCGR: interpretable deep neural network for predicting both site-level and gene-level functional targets of microRNA
MicroRNAs (miRNAs) are critical regulators in various biological processes to cleave or repress translation of messenger RNAs (mRNAs). Accurately predicting miRNA targets is essential for developing miRNA-based therapies for diseases such as cancer and cardiovascular disease. Traditional miRNA target prediction methods often struggle due to incomplete knowledge of miRNA-target interactions and lack interpretability. To address these limitations, we propose miCGR, an end-to-end deep learning framework for predicting functional miRNA targets. MiCGR employs 2D convolutional neural networks alongside an enhanced Chaos Game Representation (CGR) of both miRNA sequences and their candidate target site (CTS) on mRNA. This advanced CGR transforms genetic sequences into informative 2D graphical representations based on sequence composition and subsequence frequencies, and explicitly incorporates important prior knowledge of seed regions and subsequence positions. Unlike one-dimensional methods based solely on sequence characters, this approach identifies functional motifs within sequences, even if they are distant in the original sequences. Our model outperforms existing methods in predicting functional targets at both the site and gene levels. To enhance interpretability, we incorporate Shapley value analysis for each subsequence within both miRNA sequences and their target sites, allowing miCGR to achieve improved accuracy, particularly with more lenient CTS selection criteria. Finally, two case studies demonstrate the practical applicability of miCGR, highlighting its potential to provide insights for optimizing artificial miRNA analogs that surpass endogenous counterparts.
- 7 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6177-6192
Prediction of Multi-Pharmacokinetics Property in Multi-Species: Bayesian Neural Network Stacking Model with Uncertainty
- 7 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6177-6192
Prediction of Multi-Pharmacokinetics Property in Multi-Species: Bayesian Neural Network Stacking Model with Uncertainty
- 6 June 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (6) , 688-700
Generic protein–ligand interaction scoring by integrating physical prior knowledge and data augmentation modelling
- 6 June 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (6) , 688-700
Generic protein–ligand interaction scoring by integrating physical prior knowledge and data augmentation modelling